Sleep, Genes, and Alzheimer’s: AQP4 Variants Modulate Brain Changes

Researchers from Edith Cowan University, CSIRO, and the Australian Imaging, Biomarkers and Lifestyle (AIBL) cohort examined 351 cognitively normal adults (mean age 75) who already exhibited amyloid-beta accumulation. Published in the June 2026 issue of *Alzheimer’s & Dementia*, the study combined self-reported sleep questionnaires with MRI, PET imaging and blood-based genotyping of 13 common aquaporin-4 (AQP4) variants—the protein that underlies the brain’s glymphatic waste-clearance system—to assess interactions between sleep habits and genetic risk.

NewsweekPsypost

Carriers of AQP4 variants rs151245 or rs2339214 experienced faster gray-matter loss when reporting less than seven hours of sleep per night. Shorter sleep onset latency amplified ventricular enlargement in rs7240333 carriers, while longer sleep duration was associated with reduced white-matter volume for rs68006382. Conversely, individuals with two copies of the rarer rs12968026 or rs3875089 variants showed slower cognitive decline despite sleep disturbances. Variant rs162007 correlated with higher baseline memory scores independent of sleep, and no variant showed a significant association with PET-measured amyloid-beta.

Psypost

The findings suggest that improving sleep may mitigate genotype-specific brain loss, supporting sleep hygiene as a modifiable target in personalized Alzheimer’s-prevention strategies.

Newsweek

Study co-authors emphasized that the results illustrate an interaction between genetics and lifestyle rather than a deterministic gene effect. They warned that clinical AQP4 testing is premature, urged replication in larger, diverse cohorts, and highlighted sleep hygiene as a public-health priority. Researchers also noted the need for safer chronic-sleep treatments.

Newsweek

Critics pointed to the study’s reliance on self-reported sleep, modest sample size, and predominance of Caucasian, highly educated participants as constraints on generalizability. They cautioned against using the findings to justify genetic screening or clinical recommendations until larger, more diverse studies confirm the patterns.

Newsweek

Some sources highlighted protective effects of certain variants under poor-sleep conditions, while others emphasized overall risk linked to short sleep, reflecting unresolved consensus on causality. The absence of amyloid-beta associations also remains unexplained.

Newsweek

• “Our study shows that individuals carrying certain AQP4 variants showed faster gray matter loss when they reported shorter sleep,” — Ayeisha Milligan Armstrong, researcher, Edith Cowan University

Newsweek

• “We know that sleep and all-cause cognitive impairment, including Alzheimer's disease, are linked,” — Dr. John Showalter, physician specializing in dementia

Newsweek

• “We cannot, and I mean absolutely cannot, ignore the fact that this study screams the importance of understanding and targeting modifiable risk factors such as sleep, aggressively and early,” — Jessica McCarthy, neuropsychologist

Newsweek

• “This moves us closer to understanding why some people decline faster than others, even when they have similar risk on paper,” — Simon Laws, director, Center for Precision Health, Edith Cowan University

Psypost

The researchers plan larger, ethnically diverse follow-up studies and laboratory work on AQP4 mechanisms, aiming to test whether sleep interventions can offset genotype-specific brain changes.

Psypost